Pre-eclampsia during pregnancy and after delivery (Paperback) | Released: 06 Mar 2020

Pre-eclampsia is a difficulty during pregnancy that is related with substantial maternal and fetal morbidity and mortality. The disease presents with new-onset hypertension and often proteinuria in the mother, which can progress to multi-organ dysfunction, including hepatic, cerebral disease and renal, if the foetus and placenta are not delivered. Maternal endothelial dysfunction due to circulating factors of fetal origin from the placenta is a symbol of pre-eclampsia. Preeclampsia is a hypertensive, multisystem disorder of pregnancy whose cause remains unknown. Although management is evidence-based, preventative measures or screening tools are lacking, treatment remains symptomatic, and delivery remains the only cure. Risk factors for the disease include maternal comorbidities, such as chronic kidney disease, hypertension and obesity; a family history of pre-eclampsia, nulliparity or multiple pregnancies; and previous pre-eclampsia or intrauterine fetal growth restriction. Pre-eclampsia is a complex disease of pregnancy with sometimes serious effects on maternal and infant morbidity and mortality. It is defined by hypertension after 20 weeks' gestation and proteinuria or other evidence of multisystem involvement. In the absence of proteinuria, hypertension together with evidence of systemic disease for example thrombocytopenia or raised levels of liver transaminases is required for diagnosis. Glomeruloendotheliosis is considered to be a characteristic lesion of pre-eclampsia, but can also arise in healthy pregnant women. The placenta has a vital role in development of this disorder. Pathogenetic mechanisms implicated in pre-eclampsia include defective deep placentation, oxidative and endoplasmic reticulum stress, autoantibodies to type-1 angiotensin II receptor, platelet and thrombin activation, intravascular inflammation, endothelial dysfunction and the presence of an antiangiogenic state, among which an imbalance of angiogenesis has emerged as one of the most important factors. Women with pre-eclampsia, a potentially deadly complication of pregnancy, produce agonistic autoantibodies against angiotensin receptor-1, a transmembrane protein that regulates blood pressure. However research has found that test (the Triage PIGF Test) blood test would be improves pregnancy and birth outcomes for mother and baby. Randomised controlled trials are now essential to draw additional conclusions about how well the test performs, and look at whether it improves outcomes compared with the methods currently used to diagnose pre-eclampsia.